Promyco Diagnostics

Company Overview

Snapshot

Founded in January 2008, Promyco Diagnostics operates with 1–10 employees. The company is currently in the R&D product stage, focusing on developing diagnostic solutions for high-risk pregnancies.

Business overview

Promyco Diagnostics specializes in developing a simple, noninvasive serology diagnostic kit for detecting urogenital Mycoplasma infection. This technology aims to assess women for their risk of developing pregnancy complications. The company addresses the challenge of antigenic variation in bacteria by utilizing a patent-protected mixture of mycoplasmal components (antigens) carefully selected from Mycoplasma isolated from patients with active inflammation. Promyco Diagnostics operates within the Health Tech & Life Sciences sector, specifically in Medical Devices and Diagnostics Devices, targeting healthcare providers and consumers, particularly in women's health.

Company Intelligence Q&A

What is Promyco Diagnostics' primary focus?

Promyco Diagnostics focuses on developing a simple and noninvasive serology diagnostic kit for detecting urogenital Mycoplasma infection to assess women for their risk of developing pregnancy complications.

What challenge does Promyco Diagnostics' technology address?

Promyco Diagnostics addresses the challenge of antigenic variation in bacteria, which makes it difficult to develop efficient serology diagnostic tests, by using a patent-protected mixture of mycoplasmal components.

What is the basis of Promyco Diagnostics' diagnostic assay?

Promyco Diagnostics developed a new assay based on a patent-protected mixture of mycoplasmal components (antigens) carefully selected from Mycoplasma isolated from patients with active inflammation.

In which sector does Promyco Diagnostics primarily operate?

Promyco Diagnostics primarily operates in the Health Tech & Life Sciences sector, with a focus on Medical Devices and Diagnostics Devices.

What is the current product stage of Promyco Diagnostics?

Promyco Diagnostics is currently in the R&D product stage, developing diagnostic solutions for high-risk pregnancies.